Reports Q4 revenue $30.1M, consensus $16.47M. “We are incredibly proud of the significant progress and momentum across our hematology and ...

Enrollment Target for Adult Sickle Cell Disease Patients Achieved in BEACON Trial ofBEAM-101; Dosing of 30 Patients and ...

Beam expects that its cash, cash equivalents and marketable securities as of December 31, 2024, will enable the company to fund its anticipated ...

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a ...

Beam Therapeutics (BEAM) delivered earnings and revenue surprises of 0.91% and 44.12%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

Ark Invest, through its ARK Fintech Innovation ETF ARKF -5.46% + Free Alerts , bought 162,143 shares of Nu Holdings Ltd. This marks a significant investment in the fintech company, reflecting Ark’s ...

In collaboration with Hitachi, the National Cancer Centre Singapore has introduced Proton Beam Therapy - a treatment designed to target tumours with precision while reducing the impact on healthy ...